[go: up one dir, main page]

PE20140195A1 - Composiciones de anticuerpo y metodos de uso - Google Patents

Composiciones de anticuerpo y metodos de uso

Info

Publication number
PE20140195A1
PE20140195A1 PE2013000655A PE2013000655A PE20140195A1 PE 20140195 A1 PE20140195 A1 PE 20140195A1 PE 2013000655 A PE2013000655 A PE 2013000655A PE 2013000655 A PE2013000655 A PE 2013000655A PE 20140195 A1 PE20140195 A1 PE 20140195A1
Authority
PE
Peru
Prior art keywords
seq
hvr
methods
antibody compositions
chain regions
Prior art date
Application number
PE2013000655A
Other languages
English (en)
Inventor
Xiaocheng Chen
Mark S Dennis
Becket L Feierbach
Ashley E Fouts
Isidro Hotzel
Bing Li
Jo-Anne S Hongo
Rajesh Vij
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45890018&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20140195(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of PE20140195A1 publication Critical patent/PE20140195A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
    • C07K16/089—Cytomegalovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

UN ANTICUERPO AISLADO QUE SE UNE A COMPLEJO I DE HCMV (CITOMEGALOVIRUS HUMANO) QUE COMPRENDE TRES REGIONES HIPERVARIABLES DE CADENA PESADA : a) HVR-H1 QUE TIENE SEQ ID N� 6, SEQ ID N� 71, ENTRE OTROS; b) HVR-H2 QUE TIENE SEQ ID N� 7, SEQ ID N� 72 ENTRE OTROS; c) HVR-H3 QUE TIENE SEQ ID N�: 8, SEQ ID N�: 75 ENTRE OTROS, Y TRES REGIONES HIPERVARIABLES DE CADENA LIVIANA a) HVR-L1 QUE TIENE SEQ ID N�: 9; SEQ ID N�: 76 ENTRE OTROS; b) HVR-L2 QUE TIENE SEQ ID N�: 10-19 ENTRE OTROS; c) HVR-L3 QUE TIENE SEQ ID N�: 20, SEQ ID N� 78 ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA Y ES UTIL PARA EL TRATAMIENTO DE LA INFECCION POR HCMV.
PE2013000655A 2010-09-29 2011-09-29 Composiciones de anticuerpo y metodos de uso PE20140195A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38773510P 2010-09-29 2010-09-29
US38772510P 2010-09-29 2010-09-29
US201161504056P 2011-07-01 2011-07-01

Publications (1)

Publication Number Publication Date
PE20140195A1 true PE20140195A1 (es) 2014-02-24

Family

ID=45890018

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2013000655A PE20140195A1 (es) 2010-09-29 2011-09-29 Composiciones de anticuerpo y metodos de uso

Country Status (21)

Country Link
US (2) US20120082666A1 (es)
EP (1) EP2621533A4 (es)
JP (1) JP2014501491A (es)
KR (1) KR20130112879A (es)
CN (2) CN103313727B (es)
AR (1) AR083214A1 (es)
AU (1) AU2011312425A1 (es)
BR (1) BR112013007514A2 (es)
CA (1) CA2811087A1 (es)
CL (1) CL2013000868A1 (es)
CO (1) CO6690799A2 (es)
CR (1) CR20130133A (es)
EA (1) EA201390467A1 (es)
EC (1) ECSP13012536A (es)
IL (1) IL225389A0 (es)
MA (1) MA34541B1 (es)
MX (1) MX2013002960A (es)
PE (1) PE20140195A1 (es)
PH (1) PH12013500616A1 (es)
SG (1) SG188657A1 (es)
WO (1) WO2012047732A2 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014024023A2 (pt) * 2012-03-28 2017-07-18 Genentech Inc anticorpos idiotípicos anti-hcmv e usos dos mesmos
WO2014099908A1 (en) * 2012-12-17 2014-06-26 Genentech, Inc. Methods for inhibiting viral infection in transplant patients
MX359794B (es) 2013-03-15 2018-10-10 Intrinsic Lifesciences Llc Anticuerpos anti-hepcidina y usos de los mismos.
RU2015155601A (ru) 2013-06-10 2017-07-14 Мерк Шарп И Доум Корп. Нейтрализующие цитомегаловирус (цмв) антигенсвязывающие белки
MY193481A (en) 2013-09-13 2022-10-17 Genentech Inc Method and compositions comprising purified recombinant polypeptides
PL3044323T3 (pl) 2013-09-13 2022-06-27 F.Hoffmann-La Roche Ag Sposoby wykrywania i ilościowego oznaczania białka komórki gospodarza w liniach komórkowych
NZ730186A (en) 2014-09-22 2020-04-24 Intrinsic Lifesciences Llc Humanized anti-hepcidin antibodies and uses thereof
MX388197B (es) 2015-08-21 2025-03-19 Hoffmann La Roche Método para la reducción de proteínas de células hospederas en cromatografía de afinidad.
GB201607979D0 (en) * 2016-05-06 2016-06-22 Liverpool School Tropical Medicine Monomeric proteins and uses thereof
KR102828931B1 (ko) * 2018-10-25 2025-07-07 케이엠 바이올로직스 가부시키가이샤 개변 CMV gB 단백질 및 이것을 포함하는 CMV 백신
WO2023034950A2 (en) * 2021-09-03 2023-03-09 Icahn School Of Medicine At Mount Sinai Anti-hcmv antibodies and antigen-binding fragments thereof
WO2024229365A1 (en) * 2023-05-03 2024-11-07 The University Of Chicago Growth hormone targeting polypeptides
CN119269807A (zh) * 2024-11-26 2025-01-07 华润昂德生物药业有限公司 一种基于SPR检测EPO与其受体EpoR的体外结合活性的方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08506325A (ja) * 1993-01-28 1996-07-09 サンド ファーマスーティカル コーポレーション サイトメガロウイルスに対するヒトモノクローナル抗体
AU3415395A (en) * 1994-08-26 1996-03-22 Eli Lilly And Company Antibody constructs with cdr switched variable regions
US6875433B2 (en) * 2002-08-23 2005-04-05 The United States Of America As Represented By The Secretary Of The Army Monoclonal antibodies and complementarity-determining regions binding to Ebola glycoprotein
US7491390B2 (en) * 2004-10-15 2009-02-17 Seattle Genetics, Inc. Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders
JP2009505640A (ja) * 2005-08-11 2009-02-12 − ロジャーズ、アルピ マトシアン 自己免疫疾患の治療及び診断のためのｔｃｒ−ｖベータ関連ペプチド
US20080003605A1 (en) * 2006-05-24 2008-01-03 The University Of Chicago Microarray analysis of light chain variable gene expression and methods of use
US7704510B2 (en) * 2006-06-07 2010-04-27 The Trustees Of Princeton University Cytomegalovirus surface protein complex for use in vaccines and as a drug target
PL2126049T3 (pl) * 2006-12-15 2011-09-30 Ribovax Biotechnologies Sa Przeciwciała przeciwko ludzkiemu wirusowi cytomegalii (HCMV)
NZ603499A (en) * 2008-07-16 2014-05-30 Inst Research In Biomedicine Human cytomegalovirus neutralizing antibodies and uses thereof

Also Published As

Publication number Publication date
AU2011312425A1 (en) 2013-04-11
MA34541B1 (fr) 2013-09-02
CO6690799A2 (es) 2013-06-17
HK1189501A1 (zh) 2014-06-13
US20150376265A1 (en) 2015-12-31
IL225389A0 (en) 2013-06-27
EP2621533A4 (en) 2015-06-17
MX2013002960A (es) 2013-05-09
EP2621533A2 (en) 2013-08-07
JP2014501491A (ja) 2014-01-23
EA201390467A1 (ru) 2013-11-29
CA2811087A1 (en) 2012-04-12
BR112013007514A2 (pt) 2019-09-24
SG188657A1 (en) 2013-05-31
US20120082666A1 (en) 2012-04-05
ECSP13012536A (es) 2013-06-28
PH12013500616A1 (en) 2013-06-03
AR083214A1 (es) 2013-02-06
CR20130133A (es) 2013-08-29
KR20130112879A (ko) 2013-10-14
CN103313727A (zh) 2013-09-18
CL2013000868A1 (es) 2014-01-24
CN104945505A (zh) 2015-09-30
WO2012047732A2 (en) 2012-04-12
WO2012047732A3 (en) 2013-05-30
CN103313727B (zh) 2015-07-22

Similar Documents

Publication Publication Date Title
PE20140195A1 (es) Composiciones de anticuerpo y metodos de uso
PE20150945A1 (es) Anticuerpos de antihemaglutinina y metodos de uso
PE20161571A1 (es) Anticuerpos anti-ox40 y metodos de uso
PE20170953A1 (es) ANTICUERPOS ANTI-CD79b Y METODOS DE USO
PE20150025A1 (es) Anticuerpos e inmunoconjugados contra ly6e y metodos de uso
PE20141693A1 (es) Metodos para tratar el cancer por el uso de antagonistas de union al eje pd-1e inhibidores de mek
MX338758B (es) Anticuerpos monoclonales humanos, derivados de celulas b humanas, y que tienen actividad neutralizante contra el virus de la influenza a.
ES2685424T3 (es) Anticuerpos anti-Jagged1 y procedimientos de uso
PE20120553A1 (es) Anticuerpos anti-fgfr3
PE20141722A1 (es) Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t
AR091701A1 (es) Anticuerpos anti-cd22 e inmunoconjugados
PE20140247A1 (es) Anticuerpos anti-cd38
AR099855A1 (es) Anticuerpos hemaglutinina del virus antiinfluenza b y métodos de uso
PE20142243A1 (es) Anticuerpos que se unen a ox40 y sus usos
PE20120878A1 (es) ANTICUERPOS ANTI-FcRH5 E INMUNOCONJUGADOS
PE20120877A1 (es) ANTICUERPOS ANTI-FcRH5 E INMUNOCONJUGADOS
PE20130393A1 (es) Anticuerpos con union de antigenos dependiente de ph
PE20170687A1 (es) Proteinas de enlace a cd127
PE20141017A1 (es) Anticuerpos del cea
PE20141562A1 (es) Anticuerpos anti-htra1 y metodos de uso
PE20170670A1 (es) Anticuerpos anti-cll-1 e inmunoconjugados
CO6220835A2 (es) Anticuerpos anti-robo4 y sus usos
PE20150002A1 (es) Anticuerpos anti-fcrn
AR096687A1 (es) Anticuerpos anti-fcrh5
PE20121579A1 (es) Proteinas de enlace al antigeno il-23 humanas

Legal Events

Date Code Title Description
FA Abandonment or withdrawal